by Jenna Smith
The answer is apparently “yes” according to Amy Scher, who is the self-proclaimed first woman to use stem cell technology to treat her debilitating case of chronic Lyme disease.
Amy went to India for the treatment and is now completely free from the chronic Lyme disease that she suffered with for years.
Others with financial viability are following her lead due to the lack of options currently available to suffering victims of chronic Lyme disease in this country.
However, in the US, a controversy continues to gather ammunition, arguing whether taxpayers should pay for something that private venture capital is quite capable of funding, and more intensely the argument over using embryos from living (and frequently viable) embryo’s.
According to the National Institute of Health, there have been great strides made in the manner in which the cells are harvested and used for treatment, but that the day when treatments are available to the general populace could be as much as ten years away. This time delay is unacceptable to those who have been suffering with Lyme disease for over ten years already.
This lengthy delay is causing people who have the personal resources to go overseas where stem cell treatment has mounting success.
Stem cells are cells found in most, if not all, multi-cellular organisms. They are characterized by the ability to renew themselves through mitotic cell division and differentiating into a diverse range of specialized cell types.
Originally, research in the stem cell field grew out of findings by Canadian scientists Ernest A. McCulloch and James E. Till in the 1960s. Little did they know what an enormous impact their findings would have on future research as scientists around the world used the premise to build castles of hope in the sky.
Depending on the research team interviewed, you might believe that stem cell therapy will rid the world of all major diseases. Unfortunately, the testing can go on for years before actual cures are approved and put into practice.
Meanwhile, people who are unwilling to wait for these issues to resolve themselves are going overseas to countries unhindered by such debate.
Their willingness to avail themselves of partially untested technology, at great financial cost and at a great physical risk speaks volumes about the desperate condition of thoses suffering with chronic Lyme disease.
One can only hope that the successful stories that float back to America will change the prospects of human life facing the fastest growing disease that knows no cure from unbearable pain to renewed health.